LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Purchased by Teacher Retirement System of Texas

Teacher Retirement System of Texas increased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 31.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 101,851 shares of the medical instruments supplier’s stock after acquiring an additional 24,586 shares during the period. Teacher Retirement System of Texas owned approximately 0.45% of LeMaitre Vascular worth $9,385,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of LMAT. Smartleaf Asset Management LLC grew its position in shares of LeMaitre Vascular by 234.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 293 shares during the period. CBIZ Investment Advisory Services LLC lifted its stake in LeMaitre Vascular by 38.5% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 117 shares in the last quarter. KBC Group NV lifted its stake in LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 410 shares in the last quarter. Empowered Funds LLC purchased a new position in LeMaitre Vascular in the 4th quarter valued at about $150,000. Finally, SG Americas Securities LLC purchased a new position in LeMaitre Vascular in the 4th quarter valued at about $158,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,009 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares in the company, valued at $456,915.68. This trade represents a 26.53 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Price Performance

LMAT opened at $83.49 on Friday. The company’s 50 day simple moving average is $94.32 and its two-hundred day simple moving average is $94.47. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of 45.62, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 1-year low of $62.39 and a 1-year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.49. The business had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. On average, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th will be issued a dividend of $0.20 per share. The ex-dividend date is Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.96%. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 41.24%.

Wall Street Analysts Forecast Growth

LMAT has been the topic of a number of research reports. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price target on the stock. Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Lake Street Capital raised their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Finally, StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $95.25.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.